$ANAB

ANAPTYSBIO, INC

AnaptysBio manages financial collaborations for Jemperli, a PD-1 antagonist licensed to GSK, and Quimilza, an IL-36R antagonist licensed to Vanda. GSK develops Jemperli for solid tumor indications, while Vanda holds an exclusive global license to develop and commercialize Quimilza for generalized pustular psoriasis. AnaptysBio earns royalties and milestone payments under its GSK collaboration, and license and transition services revenue under its Vanda collaboration; it is also eligible for royalties on Quimilza sales. Milestone rights under the Vanda license are allocated to First Tracks Biotherapeutics. Following the April 20, 2026 separation of First Tracks Biotherapeutics, AnaptysBio does not expect to conduct research and development or commercialize products directly. Its business focuses on managing its collaborations and collecting royalties and other payments. AnaptysBio is headquartered in San Diego, California, and relies on contractors and outsourced providers for its administrative, technical and operational functions.

1
0
0
$17.2M
—
EcoR1 Capital, LLC
0%
See all $ANAB insider activity →

AnaptysBio earnings beat by $0.75, revenue topped estimates

AnaptysBio (ANAB) reported Q3 EPS of $0.11, beating estimates by $0.75, with revenue at $30.27M, exceeding expectations of $18.86M. The stock is down 18.30% in 3 months but up 41.25% in 12 months. InvestingPro rates its financial health as 'great performance'.

ANAB sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 1 news story mentioning ANAB (ANAPTYSBIO, INC). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.

Recent ANAB coverage spans earnings, insider activity and market movers.

In the last 30 days, ANAB insiders filed 3 SEC Form 4 transactions — 3 purchases ($17.2M) and no sales. The most active reporter was EcoR1 Capital, LLC with 3 filings.

What's driving ANAB

AlphAI scores every news story that mentions ANAB with an AI model for sentiment and relevance, and aggregates insider trades from ANAPTYSBIO, INC's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $ANAB

Score
$ANABHighAI 8/10Earnings

ANAPTYSBIO, INC (ANAB): Anaptys Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update

ANAPTYSBIO, INC (ANAB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Anaptys Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update • Jemperli global net sales of $1.0 billion (£753 million) for the nine months ended September 30, 2026, representing 29% year-over-year growth • Jemperli approved in the U.S. as

AnaptysBio (ANAB) Reports a Tax-Driven Profit. When Will Royalties Fund Shareholder Returns?

AnaptysBio (ANAB) reported a $176.4M profit for the first half of 2024, driven by a $181.5M tax benefit. Collaboration revenue grew 23% to $27.5M, and Jemperli royalties increased 25%. Royalties could grow faster as sales reach higher tiers. The company expects $299M from the Sagard arrangement by late 2027. Operating cash flow improved, but costs and litigation risks remain.

How Return To Profit Will Impact AnaptysBio (ANAB) Investors

AnaptysBio (ANAB) reported Q4 2026 net income of $183.88M, reversing a year-earlier loss. Basic and diluted EPS were $6.06 and $4.93, respectively, with six-month net income at $131M. The shift to profitability raises questions about sustainability and market reaction, as the stock has risen over a year but fallen recently.

Related tickers